EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Long‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil

Sarah Vieira Contin, B F Nathalie Almeida, S Priscilla Filgueiras iD, A Camila Corsini, A P Daniel de Miranda, J Wander de Jeremias iD, A Olindo Martins-Filho iD, Andrea Teixeira-Carvalho, Ana Carolina Campi-Azevedo, A Dayane Otta iD, G Jaquelline de Oliveira iD, R F Guilherme Campos und 14 weitere

Canadian Journal of Infectious Diseases and Medical Microbiology · 2026-01 · 2026 (1)

DOI: 10.1155/cjid/3683298 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Canadian Journal of Infectious Diseases and Medical Microbiology, online erschienen am 09.11.2026. Verfasst von Sarah Vieira Contin und 25 weiteren Autor:innen. Beteiligte Einrichtung: Diagnosis and Therapy of Infectious Diseases and Cancer Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30…. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Oswaldo Cruz, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de Minas Gerais.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This two‐year cohort study evaluated immunogenicity, safety, and reactogenicity in 1675 Brazilian healthcare workers who received CoronaVac as a primary protocol (PP) followed by heterologous boosters. All vaccines were safe, with no serious adverse events. Reactogenicity was highest for Ad26.COV2.S (62.86%) as a second booster, followed by Covishield (58.56%) and Comirnaty (42.62%); CoronaVac PP reactogenicity was 19.58%. Total anti‐S IgG levels remained high throughout, increasing after the first booster. At 9 months post‐PP, Comirnaty‐boosted individuals showed superior responses versus CoronaVac alone, regardless of prior infection. No differences were observed between one or two boosters, age groups, or sex. Initially, previously infected participants had higher anti‐S IgG (6–9 months), but this difference disappeared post‐booster. Neutralizing antibodies against Omicron BA.1 were stronger in previously infected individuals at 6–12 months. The first booster increased neutralization in both groups; the second booster further enhanced responses in infection‐naive individuals and maintained them in previously infected participants, with sustained activity up to 24 months. Participants with prior COVID‐19 showed higher levels of immunological biomarkers early on, but this gap closed after the second booster, which elevated biomarkers in both groups. Cellular response, inferred from biomarker interactions, was generally higher in infection‐naive individuals. These results underscore the importance of heterologous booster regimens in sustaining long‐term humoral and cellular immunity against COVID‐19.

Schlagwörter

Stichwörter der Autor:innen

antibodiescytokinesvaccinationviral

Autor:innen und Institutionen

  • Diagnosis and Therapy of Infectious Diseases and Cancer Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br.
  • Experimental Pharmacology Laboratory College of Pharmacy Federal University of Ouro Preto (UFOP) 306-328 Três Street, Minas Gerais Ouro Preto 35400-000 Brazil ufop.br.
  • Integrated Biomarker Research Group Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br.
  • Cellular and Molecular Immunology Laboratory Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br.
  • Virology Research Laboratory (LPV) São José do Rio Preto Medical School (FAMERP) 5416 Brg. Faria Lima Avenue, Vila São Pedro, São Paulo São José do Rio Preto 15090-000 Brazil.
  • Base Hospital 5544 Brg. Faria Lima Avenue, Vila São José, São Paulo São José do Rio Preto 15090-000 Brazil.

ORCID-Profile: S Priscilla Filgueiras, J Wander de Jeremias, A Olindo Martins-Filho, A Dayane Otta, G Jaquelline de Oliveira, L Mauricio Nogueira, Pedro Augusto Alves, R Leda Castilho, M Tulio Lima, G F Renata Alvim, F Q Rafaella Grenfell

Förderung

  • Fundação Oswaldo Cruz
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Vieira Contin, S., Nathalie Almeida, B. F., Priscilla Filgueiras, S., Camila Corsini, A., Daniel de Miranda, A. P., Wander de Jeremias, J., Olindo Martins-Filho, A., Teixeira-Carvalho, A., Campi-Azevedo, A. C., Dayane Otta, A., Jaquelline de Oliveira, G., Guilherme Campos, R. F., Mauricio Nogueira, L., Alves, P. A., Thaís Bárbara de Silva, S., Gabriel Fernandes, R., Leda Castilho, R., Priscila Fernanda Martins, S., Adelina Lourenço, J., …, & Rafaella Grenfell, F. Q. (2026). Long‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil. Canadian Journal of Infectious Diseases and Medical Microbiology, 2026(1). https://doi.org/10.1155/cjid/3683298

Vancouver

Vieira Contin S, Nathalie Almeida BF, Priscilla Filgueiras S, Camila Corsini A, Daniel de Miranda AP, Wander de Jeremias J, et al. Long‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil. Canadian Journal of Infectious Diseases and Medical Microbiology. 2026;2026(1). doi:10.1155/cjid/3683298

BibTeX
@article{VieiraContin2026,
  author = {Vieira Contin, Sarah and Nathalie Almeida, B F and Priscilla Filgueiras, S and Camila Corsini, A and Daniel de Miranda, A P and Wander de Jeremias, J and Olindo Martins-Filho, A and Teixeira-Carvalho, Andrea and Campi-Azevedo, Ana Carolina and Dayane Otta, A and Jaquelline de Oliveira, G and Guilherme Campos, R F and Mauricio Nogueira, L and Alves, Pedro Augusto and Thaís Bárbara de Silva, S and Gabriel Fernandes, R and Leda Castilho, R and Priscila Fernanda Martins, S and Adelina Lourenço, J and Jessica de Assis, V and Érica Oliveira, L and Ana Esther de Lima, S and Tulio Lima, M and Daniel de Abreu, P B and Renata Alvim, G F and Rafaella Grenfell, F Q},
  title = {Long‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil},
  journal = {Canadian Journal of Infectious Diseases and Medical Microbiology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/cjid/3683298}
}
Kostenlos starten →